Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

Abstract: A metal-air battery and a component air cathode including a solid ionically conductive polymer material.

Abstract: A metal-air battery and a component air cathode including a solid ionically conductive polymer material.

Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Abstract: A metal-air battery and a component air cathode including a solid ionically conductive polymer material.

Abstract: A metal-air battery and a component air cathode including a solid ionically conductive polymer material.

Abstract: A metal-air battery and a component air cathode including a solid ionically conductive polymer material.

Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.

Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.

Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.

Abstract: The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.

Abstract: The invention provides a method of treating abnormal cell growth in a mammal, such as a human, by administering to the mammal a therapeutically effective amount of a composition including one or both of 5-(5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide and 5-(5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylaminoethyl)-amide, or pharmaceutically acceptable salts, solvates or hydrates thereof, for at least one cycle of an intermittent dosing regimen.

Abstract: An alkaline cell is disclosed having a cathode comprising manganese dioxide wherein the cathode is a semisolid during discharge of the cell. The cell has an anode comprising zinc and an electrolyte comprising potassium hydroxide. The semisolid cathode comprising manganese dioxide may be in the form of a putty or paste. The semisolid cathode reduces cathode polarization effects and results in increased manganese dioxide utilization (Amp-hr/g), particularly at high current drain, between about 0.5 and 2 Amp. The porosity of the cathode is between about 45% and 70%, and the volume ratio of electrolyte solution in the cathode to the solids in the cathode is at a value between about 0.7 and 2.3.

Abstract: The present invention is an improved alkaline cell wherein the capacity of each of the anode and cathode is at least 0.48 and more preferably to at least 0.5 ampere-hour per cm.sup.3 of internal cell volume. This is achieved by employing zinc densities of at least 1.4 grams of zinc per cm.sup.3 of anode volume and MnO.sub.2 densities of at least 2.7 grams of MnO.sub.2 per cm.sup.3 of cathode volume.

Abstract: A completely solid state high temperature storage cell comprised of a solid rechargeable cathode such as TiS.sub.2, a solid electrolyte which remains solid at the high temperature operating conditions of the cell and which exhibits high ionic conductivity at such elevated temperatures such as an electrolyte comprised of lithium iodide, and a solid lithium or other alkali metal alloy anode (such as a lithium-silicon alloy) with 5-50% by weight of said anode being comprised of said solid electrolyte.

Abstract: An electrochemical cell containing a polyvalent film forming metal anode, a nucleophilic non-aqueous electrolyte solvent and a free radical forming carbon halide additive dissolved in said solvent.